slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,241-6,270
Pages 296
Rows per page 30
Slide type
6,241-6,270 of 8,880
32
The slide uses a combination of a data table, a biological mechanism diagram, and a summary of clinical validation to support the therapeutic thesis.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
The slide uses a combination of a biological process diagram and a line chart showing tumor cell reduction over time.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
36
Uses a Venn-like diagram to show genetic overlap between asthma and other conditions (COPD, eczema, neuro-inflammation, urticaria) to drive specific R&D strategies.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
03
The slide uses a simple icon-based visual to anchor the core strategic goal.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
08
The slide uses a process-oriented flow diagram to explain the therapeutic strategy.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
The slide highlights the mechanism of action and key benefits of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
21
The slide uses a three-column layout to explain the scientific basis and product advantages.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
11
Includes a map of global disease burden and key product features.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
The slide uses a minimalist design with a focus on the product name and target indications, accompanied by a human-centric image.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The chart illustrates the pharmacokinetic advantage of IV delivery over oral administration.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
Includes a map of the world as a visual anchor for global disease burden.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to illustrate the binding mechanism.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a three-column layout to compare different therapeutic modalities enabled by the same platform technology.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
10
The slide uses a visual comparison framework to illustrate the mechanism of action (MOA) of the drug candidate.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
52
The slide uses a before-after-bridge style framing to contrast the problem (toxicity in standard bispecifics) with the solution (BA3182).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
05
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Logic Chain1 hit
08
Enochian Biosciences | Investor Presentation Deck | 28 slidesEnochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The diagram uses a funnel-like or layered process flow to map biological mechanisms to specific immune outcomes.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
15
The slide uses a combination of a process diagram and dot plots to validate the model's performance.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
The slide presents two bar charts comparing control, tumor, tumor+mock, and tumor+TD groups under different treatment conditions (IL2 vs aCD16).Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
26
The slide contrasts the traditional CRO outsourcing model with a direct management model to justify cost efficiency.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for therapeutic intervention.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
10
The chart is a classic waterfall plot used in oncology to show best response per patient/model.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Complication1 hit
20
The slide uses a 2D grid to map dose combinations against regulatory requirements (Project Optimus).Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet1 hit
23
Erasca | Investor Presentation Deck | 41 slidesErasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution1 hit
31
The slide uses western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority in mouse models.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Market Sizing1 hit
40
The slide uses western blot imagery to show protein expression levels (P-RSK, P-ERK, GAPDH) over time (0-72h) to prove the efficacy of ERAS-007.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations 1 hit
11
The slide uses a process flow diagram to show the integration of product, technology, and data infrastructure.FinWise Bancorp | Investor Presentation Deck | 24 slides · FinWise Bancorp
Pitch deck Investor relations Beat · SolutionLoop · Logic Chain1 hit
10
The slide uses a matrix structure to contrast 'Core Technology' vs 'Client Experience' across 'Existing Foundation' and 'Recent Enhancements'.First Foundation | Investor Presentation Deck | 45 slides · First Foundation
Pitch deck Investor relations 1 hit
26
First Foundation | Investor Presentation Deck | 45 slidesFirst Foundation | Investor Presentation Deck | 45 slides · First Foundation
Pitch deck Investor relations 1 hit